GKWIM
CBAY

Gerber Kawasaki Wealth & Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed – – 1187
2021
Q3 		$0 Buy
+2
New +$8 ﹤0.01% 1255

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's CBAY Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 2 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in CBAY in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 2 Cymabay Therapeutics shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Cymabay Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Cymabay Therapeutics position peaked at $0 in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.